Skip to Main Content

Advertisement

Issue Archive

Table of Contents

EDITORIAL

In this commissioned Review Series introduced by Associate Editor Mario Cazzola, experts review the biology and pathophysiology of prominent inherited anemias and provide updated information on their management.

BLOOD COMMENTARIES

REVIEW SERIES

Inherited Anemias

In this commissioned Review Series introduced by Associate Editor Mario Cazzola, experts review the biology and pathophysiology of prominent inherited anemias and provide updated information on their management.

In this commissioned Review Series introduced by Associate Editor Mario Cazzola, experts review the biology and pathophysiology of prominent inherited anemias and provide updated information on their management.

In this commissioned Review Series introduced by Associate Editor Mario Cazzola, experts review the biology and pathophysiology of prominent inherited anemias and provide updated information on their management.

In this commissioned Review Series introduced by Associate Editor Mario Cazzola, experts review the biology and pathophysiology of prominent inherited anemias and provide updated information on their management.

In this commissioned Review Series introduced by Associate Editor Mario Cazzola, experts review the biology and pathophysiology of prominent inherited anemias and provide updated information on their management.

CLINICAL TRIALS AND OBSERVATIONS

Ramos and colleagues report a randomized phase 2 trial of the addition of vorinostat to the EPOCH regimen in HIV-associated non-Hodgkin lymphoma, aiming to reduce latent HIV reservoirs and improve responses. Their data indicate that while EPOCH has broad efficacy, there are inferior outcomes with Myc-overexpressing lymphomas, and vorinostat adds toxicity without improving complete response rates or reducing latent HIV reservoirs.

LYMPHOID NEOPLASIA

MYELOID NEOPLASIA

Yusef and colleagues identified new metabolic vulnerabilities in acute myeloid leukemia (AML) in an ex vivo screen. They highlight a leukemia-specific dependency on aldehyde dehydrogenase 3a2 and the ability of depletion of this enzyme to potentiate killing by inducers of ferroptosis and standard chemotherapy.

PLATELETS AND THROMBOPOIESIS

Using RNA sequencing, Manne and colleagues found altered gene expression profiles in pathways associated with ubiquitination, antigen presentation, and mitochondrial dysfunction in platelets from patients with COVID-19. They also found an increase in platelet activation and aggregation that may contribute to the clinical features of the illness.

Hottz and colleagues demonstrate that the platelets of critically ill patients with COVID-19 exhibit increased platelet and platelet-monocyte aggregation in comparison with those from patients with mild infection. They also reveal that platelets from patients with COVID-19 induce monocyte tissue factor expression through P-selectin and integrin αIIb3 signaling.

THROMBOSIS AND HEMOSTASIS

In these 2 independent studies from Boston and London, the authors report cohort studies that suggest, respectively, that there is no significant increase in the risk of postdischarge thrombosis and bleeding or of venous thromboembolism specifically after admission for COVID-19, compared with that associated with other acute medical illnesses.

In these 2 independent studies from Boston and London, the authors report cohort studies that suggest, respectively, that there is no significant increase in the risk of postdischarge thrombosis and bleeding or of venous thromboembolism specifically after admission for COVID-19, compared with that associated with other acute medical illnesses.

TRANSFUSION MEDICINE

Custer and colleagues used 3 different metrics to demonstrate that HIV-positive people on antiretroviral therapy and individuals taking HIV preexposure prophylaxis are donating blood. Although the implications for blood safety are currently unknown, both scenarios potentially increase the risk of transfusion-transmitted HIV if drug therapy suppresses viremia and/or antibody levels below the levels detected by current screening assays.

Grebe et al investigated whether changing the US blood donation policy for men who have sex with men from an indefinite deferral to a deferral of 12 months from last sex increases the risk of transfusion-transmitted HIV. They found no significant difference in the risk of HIV transmission by transfusion.

LETTER TO BLOOD

BLOOD WORK

ERRATUM

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement

X